Current and future trends in whole genome sequencing in cancer

References

1. 1.↵
   2. Mayor S.

   Genome sequence of one individual is published for first time. BMJ. 2007; 335: 530–1.

   OpenUrlFREE Full Text
2. 2.↵
   2. Jones SJ,
   3. Laskin J,
   4. Li YY,
   5. Griffith OL,
   6. An J,
   7. Bilenky M, et al.

   Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 2010; 11: R82.
3. 3.↵
   2. Hamdan A,
   3. Ewing A.

   Unravelling the tumour genome: the evolutionary and clinical impacts of structural variants in tumourigenesis. J Pathol. 2022; 257: 479–93.

   OpenUrl
4. 4.↵
   2. Nik-Zainal S,
   3. Davies H,
   4. Staaf J,
   5. Ramakrishna M,
   6. Glodzik D,
   7. Zou X, et al.

   Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016; 534: 47–54.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Satam H,
   3. Joshi K,
   4. Mangrolia U,
   5. Waghoo S,
   6. Zaidi G,
   7. Rawool S, et al.

   Next-generation sequencing technology: current trends and advancements. Biology (Basel). 2023; 12: 997.

   OpenUrl
6. 6.↵
   National Huuman Genome Research Institute. DNA Sequencing Costs: Data. Available from: https://www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Costs-Data, Accessed on November 30th, 2023.
7. 7.↵
   2. Sakamoto Y,
   3. Xu L,
   4. Seki M,
   5. Yokoyama TT,
   6. Kasahara M,
   7. Kashima Y, et al.

   Long-read sequencing for non-small-cell lung cancer genomes. Genome Res. 2020; 30: 1243–57.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   2. Nakagawa H,
   3. Fujita M.

   Whole genome sequencing analysis for cancer genomics and precision medicine. Cancer Sci. 2018; 109: 513–22.

   OpenUrlPubMed
9. 9.↵
   2. Zverinova S,
   3. Guryev V.

   Variant calling: considerations, practices, and developments. Hum Mutat. 2022; 43: 976–85.

   OpenUrlCrossRef
10. 10.↵
    ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 2020; 578: 82–93.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Rheinbay E,
    3. Nielsen MM,
    4. Abascal F,
    5. Wala JA,
    6. Shapira O,
    7. Tiao G, et al.

    Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020; 578: 102–11.

    OpenUrlCrossRefPubMed
12. 12.↵
    2. Turnbull C,
    3. Scott RH,
    4. Thomas E,
    5. Jones L,
    6. Murugaesu N,
    7. Pretty FB, et al.

    The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ. 2018; 361: k1687.
13. 13.↵
    2. Schipper LJ,
    3. Samsom KG,
    4. Snaebjornsson P,
    5. Battaglia T,
    6. Bosch LJW,
    7. Lalezari F, et al.

    Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics. ESMO Open. 2022; 7: 100611.
14. 14.↵
    2. Samsom KG,
    3. Schipper LJ,
    4. Roepman P,
    5. Bosch LJ,
    6. Lalezari F,
    7. Klompenhouwer EG, et al.

    Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice. J Pathol. 2022; 258: 179–88.

    OpenUrl
15. 15.↵
    2. Cuppen E,
    3. Elemento O,
    4. Rosenquist R,
    5. Nikic S,
    6. IJzerman M,
    7. Zaleski ID, et al.

    Implementation of whole-genome and transcriptome sequencing into clinical cancer care. JCO Precis Oncol. 2022; 6: e2200245.
16. 16.↵
    Ministry of health Labor and Welfare. Action Plan for Whole Genome Analysis 2022. 2022. Available from: https://www.mhlw.go.jp/content/10901000/001073173.pdf.